Zynex (NASDAQ:ZYXI) Releases Q2 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its second quarter earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $0.08 for the period, compared to the consensus estimate of $0.07. The company issued revenue guidance of $52 million, compared to the consensus revenue estimate of $53.13 million. Zynex also updated its FY 2024 guidance to 0.500- EPS.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. HC Wainwright upped their price target on shares of Zynex from $20.00 to $21.00 and gave the company a buy rating in a report on Friday, March 1st. Royal Bank of Canada upped their price target on shares of Zynex from $13.00 to $15.00 and gave the company an outperform rating in a report on Friday, March 1st.

Zynex Stock Down 4.2 %

Shares of Zynex stock traded down $0.48 on Tuesday, hitting $10.97. The company had a trading volume of 156,977 shares, compared to its average volume of 233,517. The firm has a market capitalization of $352.90 million, a P/E ratio of 40.63 and a beta of 0.48. Zynex has a twelve month low of $6.88 and a twelve month high of $14.75. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.74 and a quick ratio of 4.03. The stock has a 50-day moving average of $12.35 and a 200-day moving average of $10.83.

Zynex (NASDAQ:ZYXI) last announced its earnings results on Thursday, February 29th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.13). Zynex had a return on equity of 16.82% and a net margin of 5.28%. The business had revenue of $47.28 million for the quarter, compared to analyst estimates of $54.53 million. During the same quarter in the previous year, the company posted $0.20 EPS. The business’s revenue for the quarter was down 3.1% compared to the same quarter last year. Research analysts predict that Zynex will post 0.49 earnings per share for the current year.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.